Warning! GuruFocus detected
3 Severe warning signs
with ALT.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Altimmune Inc
NAICS : 325412
SIC : 2834
ISIN : US02155H1014
Compare
Compare
Traded in other countries / regions
ALT.USA0A4C.UKALT1.Mexico3G0.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2005-10-06Description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 78.46 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 10.1 | |||||
| Beneish M-Score | 5.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 17 | |||||
| 3-Year EPS without NRI Growth Rate | 13.6 | |||||
| 3-Year FCF Growth Rate | 19.9 | |||||
| 3-Year Book Growth Rate | -29.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 864.47 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.28 | |||||
| 9-Day RSI | 49.54 | |||||
| 14-Day RSI | 46.78 | |||||
| 3-1 Month Momentum % | -22.06 | |||||
| 6-1 Month Momentum % | -17.46 | |||||
| 12-1 Month Momentum % | -29.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.11 | |||||
| Quick Ratio | 13.11 | |||||
| Cash Ratio | 12.6 | |||||
| Days Sales Outstanding | 10271.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.8 | |||||
| Shareholder Yield % | -2.39 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -515860 | |||||
| Net Margin % | -475295 | |||||
| FCF Margin % | -399240 | |||||
| ROE % | -61.21 | |||||
| ROA % | -55.3 | |||||
| ROIC % | -5099.95 | |||||
| 3-Year ROIIC % | 93.23 | |||||
| ROC (Joel Greenblatt) % | -18732.76 | |||||
| ROCE % | -59.27 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.39 | |||||
| Price-to-Tangible-Book | 3.4 | |||||
| EV-to-EBIT | -3.31 | |||||
| EV-to-Forward-EBIT | -2.29 | |||||
| EV-to-EBITDA | -3.32 | |||||
| EV-to-Forward-EBITDA | -2.67 | |||||
| EV-to-Revenue | 15746.45 | |||||
| EV-to-Forward-Revenue | 31723.94 | |||||
| EV-to-FCF | -3.94 | |||||
| Price-to-Net-Current-Asset-Value | 3.46 | |||||
| Price-to-Net-Cash | 3.63 | |||||
| Earnings Yield (Greenblatt) % | -30.21 | |||||
| FCF Yield % | -17.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Altimmune Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.02 | ||
| EPS (TTM) ($) | -1.34 | ||
| Beta | -0.25 | ||
| 3-Year Sharpe Ratio | 0.51 | ||
| 3-Year Sortino Ratio | 1.56 | ||
| Volatility % | 57.05 | ||
| 14-Day RSI | 46.78 | ||
| 14-Day ATR ($) | 0.41929 | ||
| 20-Day SMA ($) | 5.81125 | ||
| 12-1 Month Momentum % | -29.42 | ||
| 52-Week Range ($) | 5.14 - 11.16 | ||
| Shares Outstanding (Mil) | 77.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Altimmune Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Altimmune Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Altimmune Inc Frequently Asked Questions
What is Altimmune Inc(ALT)'s stock price today?
The current price of ALT is $5.81. The 52 week high of ALT is $11.16 and 52 week low is $5.14.
When is next earnings date of Altimmune Inc(ALT)?
The next earnings date of Altimmune Inc(ALT) is 2025-05-09 Est..
Does Altimmune Inc(ALT) pay dividends? If so, how much?
Altimmune Inc(ALT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers